Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Nirmatrelvir+ritonavir

Lack of efficacy, off-label and drug exposure in pregnancy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Toure BB, et al. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstetrics and Gynecology 143: 273-276, Feb 2024. Available from: URL: https://dx.doi.org/10.1097/AOG.0000000000005471 Toure BB, et al. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstetrics and Gynecology 143: 273-276, Feb 2024. Available from: URL: https://​dx.​doi.​org/​10.​1097/​AOG.​0000000000005471​
Metadaten
Titel
Nirmatrelvir+ritonavir
Lack of efficacy, off-label and drug exposure in pregnancy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55753-5

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Iopromide

Case report

Prednisone